NKTR Latest Press Releases

-- October 1, 2026 --

/UPDATE -- Nektar Therapeutics/ PRNewswire 9:44 AM

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 PRNewswire 7:30 AM

-- September 30, 2026 --

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis PRNewswire 10:30 AM

-- September 28, 2026 --

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 PRNewswire 8:01 AM

-- September 25, 2026 --

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:15 PM

-- August 28, 2026 --

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:15 PM

-- August 25, 2026 --

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis PRNewswire 8:31 AM

-- August 13, 2026 --

Nektar Therapeutics Announces Second Quarter 2026 Financial Results PRNewswire 4:15 PM

-- August 11, 2026 --

Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm PRNewswire 7:50 AM

-- July 28, 2026 --

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets PRNewswire 6:00 PM

-- July 24, 2026 --

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:15 PM

-- July 21, 2026 --

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis PRNewswire 7:00 AM

-- June 26, 2026 --

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:30 PM

-- June 3, 2026 --

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:15 PM

-- May 27, 2026 --

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York PRNewswire 6:16 PM

Market Data Delayed 15 Minutes